News Releases

February 13, 2019 at 7:30 PM EST

Summary Toggle CryoLife Reports Fourth Quarter and Full Year 2018 Financial Results

ATLANTA , Feb. 13, 2019 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Total revenues were $67.8 million in the fourth quarter of 2018, reflecting year over year growth of 28% and an 8% increase on a non-GAAP constant currency basis compared to the fourth quarter of 2017 On-X ®
February 1, 2019 at 5:00 PM EST

Summary Toggle CryoLife Announces Release Date and Teleconference Call Details for 2018 Fourth Quarter and Year-end Financial Results

ATLANTA , Feb. 1, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2018 fourth quarter and year-end financial results will be released on Wednesday, February 13, 2019 after the market closes.
October 31, 2018 at 5:04 PM EDT

Summary Toggle CryoLife Reports Third Quarter 2018 Results

ATLANTA , Oct. 31, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the third quarter ended September 30, 2018 . Third Quarter and Recent Business Highlights: Total revenues
October 15, 2018 at 5:00 PM EDT

Summary Toggle CryoLife Reports Preliminary Financial Results for Third Quarter 2018 in Anticipation of Discussions with Senior Lenders Regarding Repricing Senior Credit Facility

Announces Release Date and Teleconference Call Details for 2018 Third Quarter Financial Results ATLANTA , Oct. 15, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, in anticipation of discussions with its senior lenders
September 18, 2018 at 5:00 PM EDT

Summary Toggle CryoLife to Present at Deutsche Bank 26th Annual Leveraged Finance Conference

ATLANTA , Sept. 18, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Deutsche Bank 26 th Annual Leveraged Finance Conference on Tuesday, October 2, 2018 at The
August 6, 2018 at 5:30 PM EDT

Summary Toggle CryoLife Reports Second Quarter 2018 Results

ATLANTA , Aug. 6, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the second quarter ended June 30 , 2018. Second Quarter and Recent Business Highlights: Total revenues increased
July 26, 2018 at 8:30 AM EDT

Summary Toggle CryoLife to Present at 38th Annual Canaccord Genuity Growth Conference

ATLANTA , July 26, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 38 th Annual Canaccord Genuity Growth Conference on Thursday, August 9, 2018 at the
July 18, 2018 at 8:30 AM EDT

Summary Toggle CryoLife Announces Release Date and Teleconference Call Details for 2018 Second Quarter Financial Results

ATLANTA , July 18, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2018 second quarter financial results will be released on Monday, August 6, 2018 after the market closes. On Tuesday, August 7, 2018
June 19, 2018 at 5:00 PM EDT

Summary Toggle Marna Borgstrom Joins CryoLife Board of Directors

ATLANTA , June 19, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Marna Borgstrom to its Board of Directors effective immediately. Pat Mackin , Chairman, President, and Chief Executive
June 11, 2018 at 5:08 PM EDT

Summary Toggle CryoLife Announces Peer Review Publication of On-X® Aortic Heart Valve PROACT Study

ATLANTA , June 11, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, today announces the publication of our clinical study entitled "Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement"